Evidence map›Paper›PMID 41807802›Full record

ArticleReproductive sciences (Thousand Oaks, Calif.)2026

Normal Fertility of Dnajb13 (exon2 KO)/(exon2 c.106T > C Mut) Compound Heterozygous Mutant Male Mice.

Wei Lei, Rui Ming, Yuehan Shen, Gang Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wei LeiInstitute of Reproductive and Stem Cell Engineering, NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, 410078, China.
Rui MingInstitute of Reproductive and Stem Cell Engineering, NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, 410078, China.
Yuehan ShenDepartment of Clinical laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Gang LiuInstitute of Reproductive and Stem Cell Engineering, NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, 410078, China. liugang7378@sina.com.ORCID 0000-0002-8448-9784

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthenozoospermia is a common factor in male infertility, and male infertility associated with primary ciliary dyskinesia (PCD) is usually caused by asthenozoospermia. Previously, we identified a heterozygous mutation DNAJB13 c.106T > C (p.Ser36Pro) in 9 patients with idiopathic oligozoospermia. Carriers exhibit reduced sperm motility, decreased DNAJB13 protein levels, abnormal localization of DNAJB13 protein in sperm, and male infertility. To investigate the mechanistic role of this mutation, we generated a Dnajb13 compound heterozygous mouse model (exon2 KO/exon2 c.106T > C Mut). Contrary to human phenotypes, Dnajb13 c.106T > C heterozygous mice showed no significant defects in spermatogenesis or fertility. These results indicate a species-specific discrepancy in the phenotypic expression of this missense mutation. We therefore propose that the DNAJB13 c.106T > C variant should be classified as a “variant of uncertain significance”.

Indexed as

ExonsFertilityHSP40 Heat-Shock ProteinsAnimalsHeterozygoteInfertility, MaleMaleMiceMice, KnockoutMutation, MissensePhenotypeSpermatogenesisHSP40 Heat-Shock ProteinsAsthenozoospermiaCompound heterozygous mutationDnajb13Missense mutation

Identifiers

PMID41807802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.